ta 993 has been researched along with aspirin in 3 studies
*Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) [MeSH]
*Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) [MeSH]
Studies (ta 993) | Trials (ta 993) | Recent Studies (post-2010) (ta 993) | Studies (aspirin) | Trials (aspirin) | Recent Studies (post-2010) (aspirin) |
---|---|---|---|---|---|
10 | 0 | 0 | 48,947 | 6,817 | 13,778 |
Protein | Taxonomy | ta 993 (IC50) | aspirin (IC50) |
---|---|---|---|
Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.35 | |
Integrin beta-3 | Homo sapiens (human) | 5 | |
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.8252 | |
Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 1.375 | |
Integrin alpha-IIb | Homo sapiens (human) | 5 | |
Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.271 | |
Substance-P receptor | Cavia porcellus (domestic guinea pig) | 2.4 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 2.15 | |
Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 0.3 | |
4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | 2.4 | |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.35 | |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4081 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Doi, H; Kaburaki, M; Murata, S; Narita, H; Yasoshima, A | 1 |
Katoh, M; Kikkawa, K; Odawara, A; Sasaki, Y; Shimazaki, T; Toryu, H | 1 |
Doi, H; Karasawa, T; Katoh, M; Odawara, A | 1 |
3 other study(ies) available for ta 993 and aspirin
Article | Year |
---|---|
Antithrombotic effect of TA-993, a novel 1,5-benzothiazepine derivative, in conscious rats.
Topics: Administration, Oral; Animals; Antithrombins; Aspirin; Diltiazem; Dose-Response Relationship, Drug; Embolism; Male; Microscopy, Electron; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Thrombosis; Ticlopidine; Time Factors | 1995 |
Inhibitory effects of TA-993, a new 1,5-benzothiazepine derivative, on platelet aggregation.
Topics: Animals; Aspirin; Basilar Artery; Calcium; Diltiazem; Dogs; Dose-Response Relationship, Drug; Electrophysiology; Fibrinolytic Agents; Humans; Male; Mice; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Ticlopidine; Vasoconstriction | 1996 |
Effects of the antiplatelet agent TA-993 and its metabolite MB3 on the hemorheological properties of rat and human erythrocytes.
Topics: Animals; Aspirin; Blood Viscosity; Diltiazem; Dose-Response Relationship, Drug; Erythrocytes; Hemolysis; Hemorheology; Humans; Phospholipids; Platelet Aggregation Inhibitors; Rats; Ticlopidine | 2001 |